GI
VRTX icon

Gradient Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Gradient Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,736
Closed -$18.6M – 473
2026
Q1 		$18.6M Sell
41,736
-1,859
-4% -$867K 0.29% 105
2025
Q4 		$19.8M Buy
43,595
+2,618
+6% +$1.13M 0.31% 102
2025
Q3 		$16M Buy
40,977
+2,964
+8% +$1.24M 0.27% 112
2025
Q2 		$16.9M Buy
+38,013
New +$17.5M 0.31% 103
2024
Q3 		– Sell
-38
Closed -$17.8K – 1270
2024
Q2 		$17.8K Hold
38
– – ﹤0.01% 655
2024
Q1 		$15.9K Sell
38
-116
-75% -$49K ﹤0.01% 586
2023
Q4 		$62.7K Sell
154
-25
-14% -$9.23K ﹤0.01% 500
2023
Q3 		$62.2K Buy
179
+157
+714% +$54.9K ﹤0.01% 460
2023
Q2 		$7.74K Buy
22
+10
+83% +$3.37K ﹤0.01% 859
2023
Q1 		$3.78K Buy
12
+5
+71% +$1.5K ﹤0.01% 999
2022
Q4 		$2.02K Buy
+7
New +$2.13K ﹤0.01% 1085
2021
Q4 		– Sell
-3
Closed -$1K – 1335
2021
Q3 		$1K Sell
3
-18
-86% -$3.51K ﹤0.01% 1116
2021
Q2 		$4K Sell
21
-5
-19% -$1.05K ﹤0.01% 922
2021
Q1 		$6K Sell
26
-3,315
-99% -$728K ﹤0.01% 863
2020
Q4 		$909K Sell
3,341
-113
-3% -$25.9K 0.04% 162
2020
Q3 		$940K Sell
3,454
-3,096
-47% -$854K 0.04% 162
2020
Q2 		$1.9M Sell
6,550
-989
-13% -$268K 0.09% 141
2020
Q1 		$1.79M Buy
7,539
+893
+13% +$205K 0.1% 135
2019
Q4 		$1.46M Sell
6,646
-265
-4% -$53.6K 0.06% 169
2019
Q3 		$1.17M Buy
6,911
+835
+14% +$148K 0.06% 182
2019
Q2 		$1.11M Buy
+6,076
New +$1.06M 0.06% 180
2018
Q1 		– Sell
-13
Closed -$2K – 1174
2017
Q4 		$2K Buy
+13
New +$1.93K ﹤0.01% 838

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Gradient Investments's VRTX Position: Q2 2026 in Review

Gradient Investments sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 41,736 shares — an estimated $18.6M sold.

Gradient Investments first reported a position in VRTX in Q4 2017 and held it in 22 quarters. The position peaked at $19.8M in Q4 2025. 302 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Gradient Investments reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Gradient Investments sold 41,736 Vertex Pharmaceuticals shares in Q2 2026, an estimated $18.6M.
  • Gradient Investments first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 22 quarters.
  • Gradient Investments's Vertex Pharmaceuticals position peaked at $19.8M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Gradient Investments's 13F filing for Q2 2026, filed 8 Jul 2026.